ReviewJournal of materials science. Materials in medicine2026
Nanostructured electrode materials and flexible-substrate engineering for wearable multi-analyte biosensors in diabetes monitoring and personalized care: a comprehensive review.
Review in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This review examines the convergence of wearable biosensors and artificial intelligence (AI) in personalized diabetes care. It addresses the limitations of traditional glucose monitoring and underscores the need for continuous, multi-analyte physiological surveillance. The manuscript evaluates multi-biofluid sensing platforms, specifically those utilizing interstitial fluid (ISF), sweat, saliva, tears, and urine. ISF, an extracellular medium and a plasma ultrafiltrate, exhibits low protein content, a property that reduces sensor biofouling. ISF glucose demonstrates a strong correlation with blood glucose (R² > 0.95) and can achieve high analytical sensitivity and specificity in clinically validated systems; however, diffusion-based time lags of 5-10 min present a kinetic challenge. Consequently, AI correction is necessary to ensure real-time accuracy, which is often achieved through minimally invasive microneedle arrays. Sweat analysis allows for non-invasive, multi-parameter measurements. Nevertheless, challenges such as pH instability and analyte loss due to evaporation complicate this sensing approach. Therefore, microfluidic techniques are essential for maintaining sample stability. A primary finding indicates that clinically validated Continuous Glucose Monitoring (CGM) systems yield substantial improvements in glycemic control, increasing Time in Range (TIR) by 10-15% and reducing the incidence of hypoglycemic events by 30-40%. AI-based predictive algorithms can forecast glucose excursions 30-60 min in advance, exhibiting an accuracy exceeding 94%. Key barriers to implementation include sensor calibration challenges, algorithmic bias, and significant healthcare equity issues. Future research should prioritize the development of multi-analyte implantable devices, leverage federated learning frameworks, and incorporate additional biomarkers to deliver continuous, multi-analyte, skin-conformal monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.